Bio Products Laboratory
This is a non-interventional, multicenter, post-marketing registry study in three patients with moderate or severe hereditary FX deficiency, to assess Coagadex administered peri-operatively for hemostatic cover in major surgery during routine post-marketing use.
Factor 10 Deficiency
Coagadex
The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor X (FX) deficiency. The secondary objective is to review safety data on Coagadex through the collection of any Adverse Drug Reactions (ADRs) from the first dose of Coagadex in the hospital prior to the surgical procedure until the first follow-up after discharge (i.e., follow-up completed) and Serious ADRs up until the post-operative care follow-up has been completed. Data on any deaths and pregnancies reported within this time period will be collected.
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 3 participants |
Official Title : | A Multicenter, Post-Marketing Registry Study of COAGADEX® in the Peri-operative Management of Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery |
Actual Study Start Date : | 2018-02-27 |
Estimated Primary Completion Date : | 2021-10-13 |
Estimated Study Completion Date : | 2021-10-13 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 12 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of Florida Health
Gainesville, florida, United States, 32610
Not yet recruiting
Tulane University Hospitals and Clinics
New Orleans, Louisiana, United States, 70112
Not yet recruiting
West Michigan Cancer Center
Kalamazoo, road cancer, United States, 49007